Trading Strategy – iShares NASDAQ Biotechnology ETF
Stocks consolidated near the flat line during Tuesday morning session before afternoon buying interest helped lift the indices modestly higher. Most cyclical sectors (with the exception of materials...
View ArticleTrading Ideas That Paid – iShares Nasdaq Biotechnology ETF
Stocks closed higher for a second session Wednesday, with the Dow logging its biggest gain in over a month, following the Fed’s upbeat Beige Book report and as the White House pressed its case for...
View ArticleTrading Strategy – iShares Nasdaq Biotechnology
The iShares Nasdaq Biotechnology ETF (IBB) posted a three-day win streak but off the intraday high, up 0.87% to 270.65. Year-to-date, IBB is still 20 percent lower. Below is an update look at a...
View ArticleTrading Strategy – iShares Nasdaq Biotechnology
The iShares Nasdaq Biotechnology ETF (IBB) surged 5.99% Wednesday, its best day since March 12, 2009. Below is an update look at a trade in IBB. The graphics below are from our “U.S. Market Trading...
View ArticleTrading Strategy – iShares NASDAQ Biotechnology ETF
iShares NASDAQ Biotechnology ETF (IBB) printed a fresh 52-week high Thursday, up 1.03 percent to 322.92. Now the question is whether the rally has some legs? According to our “U.S. Market Trading...
View ArticleTrading Strategy – iShares NASDAQ Biotechnology
The iShares NASDAQ Biotechnology ETF (IBB) fell nearly 3 percent last week, giving back most of the late June-July rally after the White House and the Republican-majority Congress failed to repeal...
View ArticleTrading Strategy – iShares NASDAQ Biotechnology Index ETF
Short sellers should be worries that biotech is leading the market higher Wednesday. The iShares NASDAQ Biotechnology Index ETF (IBB) jumped 2.05% to 324.32. YTD, it’s up more than 22% while the...
View ArticleTrading Strategy – iShares Nasdaq Biotechnology ETF
Healthcare stocks come back into the spotlight following report that Senate Majority Leader Mitch McConnell plans to bring a last-ditch bill to repeal and replace big parts of Obamacare to a vote in...
View ArticleTrading Strategy – iShares Nasdaq Biotechnology ETF
One of the more noteworthy developments in recent days has been the move in biotech. The iShares Nasdaq Biotechnology ETF (IBB) now up about 12% from its November lows to trade at 112, near two-year...
View ArticleTrading Strategy – iShares Nasdaq Biotechnology ETF
Biotech caught a bid Friday after Biogen announced positive results from a study on a drug aimed at treating early Alzheimer’s disease, its shares rose nearly 20 percent. The iShares Nasdaq...
View ArticleTrading Strategy – iShares Nasdaq Biotechnology ETF
One of the more noteworthy developments in recent days has been the move in biotech stocks. The group attracted strong buying support in recent day that saw the iShares Nasdaq Biotechnology ETF...
View ArticleS&P in Orderly High Level Consolidation Phase
recent trading actions leaving the S&P in what looks to us like an orderly high level consolidation of the March rally. The index is ticking ever closer to 2900, a level it has not breached since...
View ArticleWaning Upside Momentum Forewarn Lower Stocks Prices
daily chart of the S&P has shown significant signs that momentum is waning, suggesting that the index vulnerable to some downside retracement over the short-to-intermediate term. If S&P fails...
View ArticleAdditional Consolidations Could Unfold Between S&P’s 3100 And 3200 Zone
S&P stuck in sideways trading pattern for more than a week since breaking out in late June. Short-term technical outlook remains positive but upside momentum does not appear strong enough to...
View ArticleS&P New Highs Might Not Sustain
the fact that market is overbought as S&P poked its head into the level that had been successful in repelling price action in the past does not favor a sustain breakout. The overall technical...
View ArticleS&P Established Near-term Low
Monday’s bullish reversal signal suggested that an important near-term low has been established and the S&P is in an early stage of an oversold rally. However, given the looming resistance near...
View ArticleCautiously Optimistic
Friday’s impressive recovery rally helped putting the bulls back onto the driver side of the market but it doesn’t mean that we’re out of the woods. Given the looming resistance near S&P’s 3350,...
View ArticleS&P In Short-term Overbought Correction But Pullback Could Be Shallow And Quick
an overbought pullback consolidation interrupted the multi-month rally in the S&P. Although seemingly vulnerable to further short-term weakness, the overall technical backdrop remains positive so...
View ArticleBuying Pressure Deteriorated As S&P Tested Key Level
the big picture remains the same. There is an orderly pullback consolidation, which represents digestion period. However, the fact that buying pressure deteriorated as the S&P tested key price...
View ArticleS&P At Inflection Point
S&P is in a midst of short-term consolidation phase that reflects an indecisive market. While near-term technical bias remains bearish, downside momentum does not appear strong enough to generate...
View Article